Barclays bullish on Biomea, Replimune, Syndax, Iovance for 2H 2023 (NASDAQ:BMEA)
Oli Scarff Barclays says it has chosen Biomea Fusion (NASDAQ:BMEA), Replimune (NASDAQ:REPL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Iovance Biotherapeutics (NASDAQ:IOVA) as ...